Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phentolamine Mesylate in Open Angle Glaucoma or Ocular Hypertension
NCT03960866Phase 2Completed
- Sponsor
- Opus Genetics
- Start
- May 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of phentolamine in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Opus Genetics. Primary endpoint: Intraocular Pressure at 15 days. Started May 2019; status: completed.
02
Drugs
phentolamine
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT03960866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960866.